Shire (LON:SHP) had its price objective decreased by stock analysts at Berenberg Bank from GBX 6,000 ($82.90) to GBX 4,500 ($62.17) in a research note issued to investors on Friday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Berenberg Bank’s price objective indicates a potential upside of 48.17% from the company’s previous close.
SHP has been the topic of several other research reports. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a GBX 5,300 ($73.22) price target on shares of Shire in a research note on Monday, October 30th. Shore Capital reiterated a “buy” rating on shares of Shire in a research note on Monday, January 15th. Deutsche Bank reduced their target price on shares of Shire from GBX 5,000 ($69.08) to GBX 4,500 ($62.17) and set a “buy” rating on the stock in a report on Thursday, February 15th. Barclays restated an “equal weight” rating and issued a GBX 4,000 ($55.26) target price on shares of Shire in a report on Monday, October 30th. Finally, Kepler Capital Markets restated a “buy” rating and issued a GBX 4,600 ($63.55) target price on shares of Shire in a report on Friday, November 17th. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of GBX 4,985.29 ($68.88).
Shares of Shire (LON SHP) opened at GBX 3,037 ($41.96) on Friday. The company has a market cap of $27,780.00 and a price-to-earnings ratio of 2,094.48. Shire has a one year low of GBX 2,940.50 ($40.63) and a one year high of GBX 5,067 ($70.01).
COPYRIGHT VIOLATION NOTICE: “Berenberg Bank Cuts Shire (SHP) Price Target to GBX 4,500” was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://stocknewstimes.com/2018/02/23/berenberg-bank-cuts-shire-shp-price-target-to-gbx-4500.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.